Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
GUFICBIO
Mr. Jayesh Pannalal Choksi · Mumbai, India
₹383.95
▲+0.42%Gufic Bio is riding strong revenue growth but its lofty valuation and high leverage keep the stock near the top of its 52‑week range.
Exchange
NSI
Currency
INR
Day range
₹377.70 – ₹389.00
52-week range
₹268.00 – ₹448.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis68% confidence
The current price of ₹383.9 sits near the upper third of its 52‑week range, suggesting limited upside unless earnings accelerate or valuation compresses.
14.3% below the 1-year high · trend up
Hedge-fund memo
Today
Shares edged up 0.42% on modest buying pressure within a narrow ₹377.7‑₹389 range.
This week
The stock has been range‑bound, trading near the 52‑week high after a series of positive earnings releases.
This month
Momentum remains limited; price has hovered between ₹350‑₹395, reflecting investor caution over high P/E and debt.
Bull thesis
Bear thesis
Narrative read
Neutral
Composite sentiment
Institutional
Low (3.3% ownership, limited activist interest)
Retail
Mixed, with modest buying on earnings beats
News flow
Recent product launch announcements and a modest dividend payout
Read
Absence of analyst coverage keeps sentiment muted.
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
0.51 vs 0.61
-16.39% surprise
0.39 vs 0.79
-50.63% surprise
0.75 vs 0.61
22.95% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| GUFICBIO | 38.50B | 60.09 | 10.14% | 15.71% | 22.80% |
| HIKAL | 26.76B | — | — | 13.16% | 37.30% |
| INDOCO | 19.97B | 637.32 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High leverage and rising interest rates
Mitigation: Monitor debt reduction plans and cash‑flow coverage ratios.
Regulatory pricing pressure on generics
Mitigation: Diversify into specialty and export markets to offset margin compression.
Business intelligence
Competitive moat
A niche specialty portfolio and contract‑manufacturing capabilities give Gufic Bio a modest differentiation edge in a commoditized generic market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Q3 earnings release
Regulatory approval for new specialty drug
Thesis builder
Bull case
Continued top‑line momentum and higher‑margin specialty launches could justify a re‑rating.
Base case
Revenue growth will sustain, but valuation compression is needed for meaningful upside.
Bear case
Valuation remains stretched and debt servicing could bite if growth stalls.
Time horizon
12‑18 months
Est. CAGR
20%‑25% (revenue, 2024‑2028)
Entry (qual.)
Buy on a dip below ₹350 with a clear earnings catalyst.
Exit (qual.)
Trim near ₹440 or if P/E stays above 55× without earnings acceleration.
Overall conviction 68%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how GUFICBIO fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain GUFICBIO for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Maintain exposure but wait for a pull‑back or earnings‑beat catalyst before adding.
Annual income statement, oldest → newest. Live via Yahoo.
0.67968 vs 0.37
83.70% surprise
| 1.39% |
| 6.80% |
| KOPRAN | 9.08B | 35.29 | 4.91% | 15.42% | 35.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹377.70
Resistance (day/52w high)
₹389.00
Volume
32,344
Trend
up
RSI (14)
47
MACD
bearish
MA cross
golden
50-day MA
₹368.16
200-day MA
₹326.59
vs 200-DMA
17.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.